Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 4.68 | uM | 7552.095 | 1.0015 | 1.0027 | 1.1106 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 23.4 | uM | 7552.095 | 0.9606 | 0.9289 | 1.1106 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 117 | uM | 7552.095 | 1.0053 | 1.0095 | 1.1106 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 585 | uM | 7552.095 | 0.5355 | 0.1397 | 1.1106 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 2920 | uM | 7552.095 | 0.5466 | 0.1609 | 1.1106 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.00749 | uM | 7553.095 | 0.9701 | 0.9477 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.0374 | uM | 7553.095 | 0.9627 | 0.9348 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.187 | uM | 7553.095 | 0.7322 | 0.5242 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.936 | uM | 7553.095 | 0.6912 | 0.4496 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 4.68 | uM | 7553.095 | 0.7240 | 0.5093 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 23.4 | uM | 7553.095 | 0.6654 | 0.4022 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 117 | uM | 7553.095 | 0.6980 | 0.4620 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 585 | uM | 7553.095 | 0.6631 | 0.3980 | 1.1473 | |
| ZR-75-1 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 2920 | uM | 7553.095 | 0.6934 | 0.4536 | 1.1473 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.00749 | uM | 7555.095 | 0.9453 | 0.9393 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.0374 | uM | 7555.095 | 0.9545 | 0.9496 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.187 | uM | 7555.095 | 0.6508 | 0.5800 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 0.936 | uM | 7555.095 | 0.6223 | 0.5418 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 4.68 | uM | 7555.095 | 0.6783 | 0.6164 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 23.4 | uM | 7555.095 | 0.6299 | 0.5521 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 117 | uM | 7555.095 | 0.6428 | 0.5694 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 585 | uM | 7555.095 | 0.6678 | 0.6026 | 1.8227 | |
| ZR75B | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 2920 | uM | 7555.095 | 0.6843 | 0.6242 | 1.8227 | |
| BT-20 | TNBC | Basal A | Pertuzumab | 0.0000032 | mg/ml | 5903.102 | 0.9980 | 0.9969 | 1.2557 | |||
| BT-20 | TNBC | Basal A | Pertuzumab | 0.000016 | mg/ml | 5903.102 | 1.0022 | 1.0035 | 1.2557 |